Bladder Cancer
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
AstraZeneca Voluntarily Withdraws Checkpoint Inhibitor Approved for Bladder Cancer Indication
2021-02-25
ASCO 2020: Maintenance Therapy with Avelumab Post-Chemo Improves Overall Survival of Bladder Cancer Patients
2020-05-29